Baricitinib in alopecia areata: Real‐world data from a case series in Greece

Journal of the European Academy of Dermatology and VenereologyEarly View LETTER TO THE EDITOR Baricitinib in alopecia areata: Real-world data from a case series in Greece A. C. Katoulis, Corresponding Author A. C. Katoulis [email protected] orcid.org/0000-0001-8189-7486 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece Correspondence A. C. Katoulis, 2nd Department of Dermatology and Venereology, NKUA, Medical School "Attikon" General University Hospital, Athens, Greece. Email: [email protected]Search for more papers by this authorG. Pappa, G. Pappa 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorE. Markou, E. Markou 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorA. Kanelleas, A. Kanelleas 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorE. Bozi, E. Bozi 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorD. Sgouros, D. Sgouros orcid.org/0000-0003-0009-8821 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this author A. C. Katoulis, Corresponding Author A. C. Katoulis [email protected] orcid.org/0000-0001-8189-7486 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece Correspondence A. C. Katoulis, 2nd Department of Dermatology and Venereology, NKUA, Medical School "Attikon" General University Hospital, Athens, Greece. Email: [email protected]Search for more papers by this authorG. Pappa, G. Pappa 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorE. Markou, E. Markou 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorA. Kanelleas, A. Kanelleas 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorE. Bozi, E. Bozi 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this authorD. Sgouros, D. Sgouros orcid.org/0000-0003-0009-8821 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, GreeceSearch for more papers by this author First published: 03 February 2024 https://doi.org/10.1111/jdv.19822Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions. REFERENCES 1Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023; 27(3): 241–259. https://doi.org/10.1177/12034754231168839 10.1177/12034754231168839 PubMedWeb of Science®Google Scholar 2Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020; 82(3): 675–682. https://doi.org/10.1016/j.jaad.2019.08.032 10.1016/j.jaad.2019.08.032 CASPubMedWeb of Science®Google Scholar 3Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of Baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023; 24(3): 443–451. https://doi.org/10.1007/s40257-023-00764-w 10.1007/s40257-023-00764-w PubMedWeb of Science®Google Scholar 4Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023; 83: 761–770. https://doi.org/10.1007/s40265-023-01873-w 10.1007/s40265-023-01873-w CASPubMedWeb of Science®Google Scholar 5King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of Baricitinib for alopecia areata. N Engl J Med. 2022; 386(18): 1687–1699. https://doi.org/10.1056/NEJMoa2110343 10.1056/NEJMoa2110343 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation